Apellis is a clinical-stage biopharma company focused on developing novel therapeutic compounds to treat disease through the inhibition of the complement system, an integral part of the immune system, at the level of C3, the central protein in the complement cascade. We believe that this approach can result in broad inhibition of the principal pathways of the complement system and has the potential to effectively control a broad array of complement-dependent autoimmune and inflammatory diseases.